News Releases Year None20232022202120202019 Date Title Additional Formats September 26, 2023 Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD September 5, 2023 Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences August 21, 2023 Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application August 10, 2023 Phathom Pharmaceuticals Reports Second Quarter 2023 Results June 12, 2023 Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD June 9, 2023 Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock June 1, 2023 Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences May 23, 2023 Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock May 23, 2023 Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock May 23, 2023 Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18